相关实验视频

Updated: Jul 2, 2025

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction

Published on: September 14, 2018

抗体-药物结合物概述:一个最先进的制造工艺和控制策略

Meng Li¹, Xueyu Zhao², Chuanfei Yu¹

¹NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, National Institutes for Food and Drug Control, Beijing, People's Republic of China.

Pharmaceutical research

|February 17, 2024

概括

抗体-药物合物 (ADC) 通过将抗体与强效药物结合起来,提供向癌症治疗. 本次审查强调了ADC设计,制造和质量控制方面的进展,以确保有效性和患者安全.

科学领域:

生物技术是生物技术.
制药科学制药科学
在瘤学瘤学.

背景情况:

抗体-药物联合体 (ADCs) 是复杂的疗法,结合了抗体,链接剂和强效药物,用于向瘤细胞的输送.
产品的异质性源于ADC结构和制造工艺的固有变化.
优化ADC疗效需要对抗体,链接剂和药物成分进行精心设计,以最大限度地降低毒性.

研究的目的:

审查ADCs的历史,临床开发和分子设计的最新进展.
讨论ADC制造工艺和质量控制策略的关键方面.
确定ADC发展当前的挑战和未来的前景.

主要方法:

对最近ADC技术的关键进展进行文献综述.
对临床开发状态和分子设计原则的分析.
检查制造工艺,合技术和质量控制措施.

主要成果:

ADCs代表了针对性癌症治疗的重大进步.
强大的制造和严格的质量控制对于ADC的安全性和有效性至关重要.
以患者为中心的策略和设计质量 (QbD) 对ADC产品开发和生命周期管理至关重要.

结论:

在ADC设计和制造方面不断的创新对于克服治疗挑战至关重要.
解决固有的异质性和确保一致的质量是成功ADC开发的关键.
需要跨职能研究来克服现有的障碍,并推进ADC疗法.

关键词:

抗体 - 药物联合体关键的质量属性关键的质量属性细胞毒性药物细胞毒性药物链接器是一个链接器.制造过程中的制造工艺.药学研究药学研究质量控制质量控制质量控制

更多相关视频

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Length Protein for Targeting Mouse Dendritic Cells In Vitro and In Vivo

Published on: February 5, 2021

相关概念视频

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Phase II Conjugation Reactions: Overview

Phase II Conjugation Reactions: Overview

Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...